$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
MRD-guided ibrutinib/Venetoclax brings PFS benefit in CLL
2026-02-01 22:25:32
Check Details
What is the required concentration of venetoclax/venetoclax?
2026-02-01 22:25:32
Check Details
Can venetoclax/venetoclax be used long-term?
2026-02-01 22:25:32
Check Details
Is Venetoclax/Venetoclax better to be domestically produced or imported?
2026-02-01 22:25:32
Check Details
Is venetoclax/venetoclax a targeted drug or a chemotherapy drug?
2026-02-01 22:25:32
Check Details
What are the side effects of venetoclax/venetoclax and how long do they last?
2026-02-01 22:25:32
Check Details
Can I be reimbursed for Venetoclax/Venetoclax? What is the price after medical insurance?
2026-02-01 22:25:32
Check Details
Must-read for patients: Efficacy and side effects of venetoclax/venetoclax tablets
2026-02-01 22:25:32
Check Details
Where can I buy venetoclax/venetoclax tablets and how much can patients buy a box of them?
2026-02-01 22:25:32
Check Details
New hope in the fight against cancer: What diseases does Venetoclax/Venetoclax tablets treat?
2026-02-01 22:25:32
Check Details
Innovative drugs for hematological tumors: The therapeutic effect of venetoclax/venetoclax tablets
2026-02-01 22:25:32
Check Details
For leukemia, take venetoclax/venetoclax while undergoing chemotherapy. How many days should you take a course of treatment?
2026-02-01 22:25:32
Check Details
1
2
...
486
487
488
489
490
491
492
...
10222
10223
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Elagolix Side Effects and Safety Guide
2
Hetrombopag vs. Avatrombopag: Key Differences Between Two Oral TPO-RAs and Safety Considerations
3
Lytenava: The First FDA-Approved Ophthalmic Bevacizumab Formulation
4
FDA Approves Lytenava: First Ophthalmic Bevacizumab for Wet AMD
5
Simtriyo (Centanafadine): World's First NDSRI ADHD Drug Approved by FDA
6
Lipfendra (Enlicitide): The World's First Oral PCSK9 Inhibitor Approved by FDA
7
Orforglipron: The World's First Oral Small-Molecule GLP-1 Receptor Agonist for Weight Management
8
Cabozantinib Capsules: A Multi-Targeted Therapy for Progressive Medullary Thyroid Cancer
9
Lorlatinib: Mechanism, Advantages, and Key Considerations of Third-Generation ALK Inhibitor Therapy in ALK-Positive NSCLC
10
FDA Approves Subcutaneous Isatuximab (Sarclisa) for Multiple Myeloma: A New Administration Option
11
Pemigatinib Side Effects Explained: Managing Adverse Reactions of FGFR-Targeted Therapy in Cholangiocarcinoma
12
Selpercatinib: Before or After Meals? A Complete Guide to RET-Targeted Therapy Administration